Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Maintains $720 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman has maintained a 'Hold' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and kept the price target at $720.
August 18, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' stock rating has been maintained at 'Hold' by Canaccord Genuity with a price target of $720.
The news is directly about Regeneron Pharmaceuticals and its stock rating by Canaccord Genuity. The 'Hold' rating suggests that the analyst believes the stock will perform in line with the market, which is neither particularly positive nor negative. Therefore, the short-term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100